JPWO2020103788A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020103788A5 JPWO2020103788A5 JP2021551329A JP2021551329A JPWO2020103788A5 JP WO2020103788 A5 JPWO2020103788 A5 JP WO2020103788A5 JP 2021551329 A JP2021551329 A JP 2021551329A JP 2021551329 A JP2021551329 A JP 2021551329A JP WO2020103788 A5 JPWO2020103788 A5 JP WO2020103788A5
- Authority
- JP
- Japan
- Prior art keywords
- cell lymphoma
- pharmaceutical composition
- thidamide
- combination
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 208000003950 B-cell lymphoma Diseases 0.000 claims 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 229940009456 adriamycin Drugs 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 229960001904 epirubicin Drugs 0.000 claims 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 2
- 229960004618 prednisone Drugs 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 2
- 229960004528 vincristine Drugs 0.000 claims 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000890 drug combination Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811394614 | 2018-11-20 | ||
| CN201811394614.7 | 2018-11-20 | ||
| PCT/CN2019/119170 WO2020103788A1 (zh) | 2018-11-20 | 2019-11-18 | 西达本胺联合r-chop的应用及联合药物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022511126A JP2022511126A (ja) | 2022-01-28 |
| JPWO2020103788A5 true JPWO2020103788A5 (https=) | 2022-08-24 |
| JP2022511126A5 JP2022511126A5 (https=) | 2022-08-24 |
| JP7489397B2 JP7489397B2 (ja) | 2024-05-23 |
Family
ID=70741744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021551329A Active JP7489397B2 (ja) | 2018-11-20 | 2019-11-18 | Ｒ－ｃｈｏｐとの組み合わせ及び複合薬におけるチダミドの適用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12194054B2 (https=) |
| EP (1) | EP3884943B1 (https=) |
| JP (1) | JP7489397B2 (https=) |
| CN (2) | CN111195249B (https=) |
| AU (1) | AU2019385373B2 (https=) |
| BR (1) | BR112021009627A2 (https=) |
| MY (1) | MY209036A (https=) |
| PH (1) | PH12021551138A1 (https=) |
| SG (1) | SG11202105137RA (https=) |
| TW (1) | TWI768263B (https=) |
| WO (1) | WO2020103788A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121059617A (zh) * | 2020-06-18 | 2025-12-05 | 苏州亚盛药业有限公司 | 包含Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂的组合产品及其用途 |
| CN112274509B (zh) * | 2020-12-02 | 2022-04-26 | 四川大学华西医院 | 西达本胺联合bcl2抑制剂在双表达型b细胞淋巴瘤中的应用 |
| CN121513004B (zh) * | 2026-01-14 | 2026-04-03 | 首都医科大学附属北京友谊医院 | 一种治疗abc型弥漫性大b细胞淋巴瘤的组合物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100924737B1 (ko) * | 2003-08-26 | 2009-11-04 | 슬로안-케테링인스티튜트퍼캔서리서치 | Ｈｄａｃ 억제제를 이용한 암의 치료 방법 |
| CN101470112A (zh) * | 2007-12-28 | 2009-07-01 | 上海交通大学医学院附属瑞金医院 | 弥漫性大b细胞淋巴瘤治疗指导和预后判断的分子标志物 |
| CN103833626B (zh) | 2012-11-27 | 2015-11-25 | 深圳微芯生物科技有限责任公司 | 西达本胺的晶型及其制备方法与应用 |
| TWI808055B (zh) * | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| IL292457A (en) | 2016-07-20 | 2022-06-01 | Univ Columbia | Histone acetyl transferase activators, their preparations and their uses |
| CN107157978B (zh) * | 2017-05-24 | 2021-06-18 | 中国药科大学 | 治疗ebv+dlbcl和dlbcl的药物及组合物 |
| CN108743947B (zh) * | 2018-07-04 | 2020-12-15 | 复旦大学附属肿瘤医院 | 一种治疗b细胞淋巴瘤的药物组合物 |
-
2019
- 2019-03-25 CN CN201910228406.8A patent/CN111195249B/zh active Active
- 2019-03-25 CN CN202311474046.2A patent/CN117797149A/zh active Pending
- 2019-11-18 SG SG11202105137RA patent/SG11202105137RA/en unknown
- 2019-11-18 MY MYPI2021002751A patent/MY209036A/en unknown
- 2019-11-18 BR BR112021009627-2A patent/BR112021009627A2/pt unknown
- 2019-11-18 TW TW108141826A patent/TWI768263B/zh active
- 2019-11-18 US US17/295,494 patent/US12194054B2/en active Active
- 2019-11-18 EP EP19887480.2A patent/EP3884943B1/en active Active
- 2019-11-18 JP JP2021551329A patent/JP7489397B2/ja active Active
- 2019-11-18 WO PCT/CN2019/119170 patent/WO2020103788A1/zh not_active Ceased
- 2019-11-18 AU AU2019385373A patent/AU2019385373B2/en active Active
-
2021
- 2021-05-19 PH PH12021551138A patent/PH12021551138A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201210593A (en) | Compositions and methods for treating centrally mediated nausea and vomiting | |
| RU2010147287A (ru) | Комбинированная композиция | |
| JP2003292443A5 (https=) | ||
| CN107872975A (zh) | 用于治疗恶心和呕吐的氨磺必利和其它止吐药的组合 | |
| HUE029677T2 (hu) | Készítmények centrálisan mediált émelygés és hányás kezelésére | |
| US20110281833A1 (en) | Composition for the Treatment of Ear Infections and Method | |
| JP2006514092A5 (https=) | ||
| JP2022511126A5 (https=) | ||
| Odom | New therapies for onychomycosis | |
| TWI441639B (zh) | 用於治療卵巢癌之包含紫杉醇之組合 | |
| BR0315316A (pt) | Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit | |
| Veloso et al. | Topical fixed-dose combinations: a way of progress for pain management? | |
| JP2021522246A5 (https=) | ||
| JP2016505050A5 (https=) | ||
| US20190381046A1 (en) | Tofacitinib and baclofen compositions and applications | |
| JP7489397B2 (ja) | Ｒ－ｃｈｏｐとの組み合わせ及び複合薬におけるチダミドの適用 | |
| JPWO2020103788A5 (https=) | ||
| AU2007335255A1 (en) | Composition and method for treatment of IBS | |
| JPH06509072A (ja) | 化学療法により誘発される脱毛の予防および治療法 | |
| CN1332663C (zh) | 用硝酸咪康唑治疗外阴阴道念珠菌病的药盒 | |
| CN105055205A (zh) | 一种药物牙膏及其制备方法 | |
| CN103203011A (zh) | 一种防治化疗后口腔溃疡的口香糖 | |
| RU2005131868A (ru) | Фармацевтическая композиция, фармацевтическая комбинация (варианты) и способы их применения | |
| WO2012059874A1 (en) | A mouthwash composition for managing oral mucositis, process and methods thereof | |
| JP2021511352A5 (https=) |